FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies

<!–

–>

<!–

• Page Last Updated: 04/08/2011

–>
Page Last Updated: 04/08/2011
<!–

–>

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.